An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate and Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Vildagliptin 25 mg and 50 mg Once Daily for 14 Days.

Trial Profile

An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate and Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Vildagliptin 25 mg and 50 mg Once Daily for 14 Days.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2009 Official Title amended as reported by ClinicalTrials.gov.
    • 16 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top